BOSTON, Jan. 6, 2011 /PRNewswire/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company looks towards continued growth in 2011 through new product development, new product sales and the completion of the requirements for its ISO 13485 quality management system (QMS) initiative, which is a major step in obtaining the CE Mark and the permission to sell medical devices in the European Union.
Early in 2010, Solos retained Expert Resource (ER) to provide consulting services in support of the Company's ISO 13485 quality management system (QMS) initiative as well as obtaining the CE Mark. Since this time, the Company has successfully completed Phase One (of Four) requirements for the Company's ISO 13485 quality management system (QMS) initiative. In addition to this milestone, Solos announced in March 2010 that the Company had secured the U.S. Trademark registration (#3637510) for the protection of the MammoView® name. Throughout 2010, the Company remained focused on new product design and development announcing the design of a new Polymer Dilator and separate Relay Lense Adapter System for the MammoView ® Product Line.
As the first six months of 2010 drew to a close, the Company appointed Fred Schiemann as CFO and Director to provide financial leadership amidst growth. Mr. Schiemann brings a strong administrative background in the small-cap company sector as well as expertise in taxation, auditing and public securities work. As a result, later in 2010, Solos followed by announcing that the Company's management had approved its 2011 recapitalization plan in order to position itself for growth over the next twelve months. The recapitalization plan allows Solos greater flexibility to utilize the assets of the Company in the future for corporate purposes; including raising capital, acquisitions or employee compensation, with